Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various indications, including low back pain, neuropathic pain, and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-2586-4657
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees70
Next Earnings Date5/21/2019 (Estimated)
OptionableOptionable
Intec Pharma (NASDAQ:NTEC) Frequently Asked Questions
What is Intec Pharma's stock symbol?
Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC."
How were Intec Pharma's earnings last quarter?
Intec Pharma Ltd (NASDAQ:NTEC) issued its quarterly earnings data on Wednesday, February, 27th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.08. View Intec Pharma's Earnings History.
When is Intec Pharma's next earnings date?
What price target have analysts set for NTEC?
5 brokerages have issued 12-month target prices for Intec Pharma's shares. Their forecasts range from $8.50 to $16.00. On average, they anticipate Intec Pharma's stock price to reach $13.30 in the next twelve months. This suggests a possible upside of 119.5% from the stock's current price. View Analyst Price Targets for Intec Pharma.
What is the consensus analysts' recommendation for Intec Pharma?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intec Pharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intec Pharma.
What are Wall Street analysts saying about Intec Pharma stock?
Here are some recent quotes from research analysts about Intec Pharma stock:
- 1. According to Zacks Investment Research, "Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson's disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. " (3/7/2019)
- 2. Maxim Group analysts commented, "Intec announced positive data from the PK study in Parkinson’s disease (PD) patients (N=12) of Accordion Pill Carbidopa/Levodopa (AP – CD/LD) demonstrating significantly reduced plasma levodopa variability as measured by levodopa fluctuation index (P<0.005). The data is reviewed below."" (2/19/2019)
- 3. LADENBURG THALM/SH SH analysts commented, "We agree that these results should be telling, since there has not been a PK study on TID 50/500mg dosing, reportedly the most common regimen in ACCORDANCE. Below, we describe this study and our expected outcomes based on prior data and AP-CD/LD’s release characteristics. We believe the most important conclusion is whether this dosing regimen can maintain stable plasma LD levels throughout the day, not any particular minimum threshold, as consistency of LD blood levels is correlated with efficacy while changes are correlated with adverse events. We do not anticipate efficacy data from this trial. PK trial design." (1/29/2019)
- 4. HC Wainwright analysts commented, "We believe the Accordion Pill’s gastric retentive technology is ideally suited to extend the absorption phase of THC, with the goal of a slower rate of rise and more consistent drug plasma levels after oral delivery. The combination of the slower rate of rise with sustained and consistent plasma levels could translate into an improved therapeutic effect and reduce the adverse events that are correlated with rate of rise and peak THC plasma levels. Following this PK study, Intec plans to initiate a PK study of AP-cannabidiol (CBD) in 1H19. AP-CBD programs utilize pharmaceutically pure synthetic cannabinoids as starting materials. In the wake of this recent advance, we reiterate our Buy rating and 12-month price target of $16.00 on NTEC." (1/4/2019)
Has Intec Pharma been receiving favorable news coverage?
Headlines about NTEC stock have been trending somewhat positive on Friday, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Intec Pharma earned a news sentiment score of 1.1 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the next several days.
Who are some of Intec Pharma's key competitors?
Some companies that are related to Intec Pharma include CannTrust (CTST), CannTrust (CNTTF), CymaBay Therapeutics (CBAY), Evolus (EOLS), Cara Therapeutics (CARA), ChemoCentryx (CCXI), Akebia Therapeutics (AKBA), Eagle Pharmaceuticals (EGRX), Arvinas (ARVN), Intra-Cellular Therapies (ITCI), TG Therapeutics (TGTX), Athenex (ATNX), ZIOPHARM Oncology (ZIOP), Principia Biopharma (PRNB) and Vital Therapies (VTL).
What other stocks do shareholders of Intec Pharma own?
Who are Intec Pharma's key executives?
Intec Pharma's management team includes the folowing people:
- Mr. Jeffrey A. Meckler, Vice Chairman & CEO (Age 52)
- Mr. Nir Sassi, Chief Financial Officer (Age 43)
- Dr. Nadav Navon Ph.D., Chief Operating Officer (Age 50)
- Mr. Walt Addison Linscott, Chief Bus. Officer (Age 58)
- Dr. R. Michael Gendreau, Chief Medical Officer (Age 63)
When did Intec Pharma IPO?
(NTEC) raised $30 million in an initial public offering on Tuesday, August 4th 2015. The company issued 5,000,000 shares at a price of $6.00 per share. Maxim Group and Roth Capital Partners served as the underwriters for the IPO.
Who are Intec Pharma's major shareholders?
Intec Pharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Harel Insurance Investments & Financial Services Ltd. (0.13%).
Which institutional investors are selling Intec Pharma stock?
NTEC stock was sold by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd..
How do I buy shares of Intec Pharma?
Shares of NTEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intec Pharma's stock price today?
One share of NTEC stock can currently be purchased for approximately $6.06.
How big of a company is Intec Pharma?
Intec Pharma has a market capitalization of $198.95 million. The biotechnology company earns $-43,540,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Intec Pharma employs 70 workers across the globe.
What is Intec Pharma's official website?
How can I contact Intec Pharma?
Intec Pharma's mailing address is 12 Hartom Street Har Hotzvim, Jerusalem L3, 9777512. The biotechnology company can be reached via phone at 972-2586-4657 or via email at [email protected]
MarketBeat Community Rating for Intec Pharma (NASDAQ NTEC)
MarketBeat's community ratings are surveys of what our community members think about Intec Pharma and other stocks. Vote "Outperform" if you believe NTEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTEC will underperform the S&P 500 over the long term. You may vote once every thirty days.
